Alcidion has raised capital

Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.

Alcidion is a market leading healthcare software informatics company providing an innovative technology platform to improve the efficiency and quality of patient care. Its flagship platform, Miya Precision, can be deployed in a modular approach to accommodate varying customer priorities and budget profiles across the UK, Australia and New Zealand markets.

At the end of September 2023, Alcidion had A$35.3 million (US$23m) of contracted revenue for FY24 (expected to grow over the remainder of the year) and is forecasting to be EBITDA and cashflow positive.

Oaklins’ team in Australia acted as lead manager in this transaction.

Service

Funding, debt advisory & ECM

Parties

Talk to the deal team

Justin Lewis

Managing Director

Melbourne, Australia
Oaklins Henslow

View profile Get in touch

Sebastian Bell

Director

Sydney, Australia
Oaklins Henslow

View profile Get in touch

Related deals

Backspin has completed a mandatory public tender offer for the shares of Spindox

Private Equity | TMT

Backspin has completed a mandatory public tender offer for the shares of Spindox

Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.

Learn more

Rare Patient Voice has been acquired by Konovo

Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more